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Management of idiopathic membranous nephropathy: Evidence- diffuse and uniform and is accompanied by little in the
based recommendations. Membranous nephropathy is a fre- way of cellular proliferation [3]. Silver staining may re-
quent cause of nephrotic syndrome in adults, and in one third veal the presence of spikes of argyrophilic material pro-of these patients, it leads to end-stage renal disease. Based on
jecting out from the GBM toward the epithelial space.an extensive critical review of the literature, the following recom-
With further progression, intense thickening of the glo-mendations are offered. Oral high-dose corticosteroids are inef-
fective in producing either a sustained remission of nephrotic merular capillary walls occurs, with reduplication of the
syndrome or in preserving renal function in patients with mem- GBM. Extensive interstitial fibrosis and tubular atrophy
branous nephropathy, and should not be used as the sole ther- are also apparent in advanced disease. Electron micros-apy (grade A recommendation). The use of azathioprine is not
copy reveals the presence of electron-dense immune de-associated with any significant benefits, so its use is not justified
posits, which on immunofluorescence are found to con-(grade C). The alkylating agents cyclophosphamide and chlor-
ambucil are both effective in the management of membranous tain IgG, usually accompanied by C3, in a characteristic
nephropathy. Because of growing concern about long-term tox- granular pattern, outlining the GBM. In very advanced
icity, especially with cyclophosphamide, these drugs should be
disease, the intensity of IgG staining may be diminished,reserved for patients who exhibit clinical features, such as se-
corresponding to the reduction in immune deposits seenvere or prolonged nephrosis, renal insufficiency, or hyperten-
sion, that predict a high likelihood of progression to end-stage on electron microscopy in late disease.
renal disease. Chlorambucil in conjunction with oral steroids
is the drug of first choice (grade A). Cyclophosphamide and Natural history and risk factors for progression
oral steroids are alternatives (grade B). Cyclosporine may, in
Attempts to define the optimal management strategythe future, become the agent of choice for membranous nephrop-
for membranous nephropathy have been substantiallyathy. Currently, it is recommended (grade B) that cyclosporine
use be considered in patients at high risk for progression in hampered by the extremely variable clinical course that
membranous nephropathy or if alkylating agents are contrain- can be seen in the disease. The challenge is to find ways of
dicated or ineffective. identifying those patients at highest risk for progressive
disease and then using cytotoxic or other therapies such
as cyclosporine. Many studies have “identified” risk fac-
Membranous nephropathy may occur secondary to tors for progression to renal failure, including severe NS,
conditions such as hepatitis B and other infections, sys- hypertension, age of more than 50 years, male sex, and
temic lupus erythematosus (SLE), therapy with various renal insufficiency at presentation [4–10]. However, few
drugs (for example, gold, penicillamine), and malignan- studies have examined such risk factors prospectively.
cies [1]. However, in adults, membranous nephropathy Recently, Pei, Cattran, and Greenwood reported a
is most often idiopathic. The disease presents most fre- predictive model, based on data in the Toronto Glomeru-
quently as the nephrotic syndrome (NS) or, less fre- lonephritis Registry, for chronic renal insufficiency in
quently, as asymptomatic proteinuria, with or without patients with idiopathic membranous nephropathy [11].
hypertension. Membranous nephropathy accounts for A variety of models, based on severity and duration of
approximately 30% of cases of NS in adults [2]. proteinuria and rate of change in renal function, was
The diagnosis of membranous nephropathy is made by able to improve the ability to predict the development
renal biopsy, with thickening of the glomerular basement of chronic renal insufficiency from a baseline level of
membrane (GBM) on light microscopy, which is both 26% to a range of 55 to 86%, with a sensitivity of more
than 60%. Such a model could be used to anticipate the
need for therapy by identifying individual patients atKey words: nephrotic syndrome, end-stage renal disease, cortico-
steroids, toxicity, chlorambucil. risk for progressive disease, and it could also be used to
identify high-risk patients for future clinical trials. The 1999 by the International Society of Nephrology
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inclusion of large numbers of patients with a good prog- confounded by the variable course of the disease and, in
nosis has been one of the major weaknesses of previous particular, by the frequent development of spontaneous
clinical trials of therapy in membranous nephropathy. remissions, sometimes many months or years after the
In a recent update that compares the Canadian data onset of NS, reported in studies of natural history [4–6,
to other patient populations in Italy and Finland, the 20]. Treatment may be considered in two broad catego-
predictive model outlined above has been validated [12]. ries: the management of symptoms and signs of NS (for
The most important factor determining long-term out- example, edema, hyperlipidemia) and therapies aimed
come in membranous nephropathy was found to be the at inducing remission of proteinuria and preventing pro-
highest sustained six-month period of proteinuria. The gression to ESRD.
model was able to predict patients at high risk of progres- Thromboembolic complications, especially renal vein
sion with an accuracy of more than 85%, despite the thrombosis, are frequent in NS in general and membra-
differences at baseline. nous nephropathy in particular. The incidence of renal
A number of studies have examined the natural history vein thrombosis in membranous nephropathy has been
and outcome of membranous nephropathy, with or with- reported at 5 to 60% [21–23]. This wide range reflects a
out therapy [4–6, 13–15]. Honkanen, Tornroth and Gron- high incidence of subclinical thrombosis, identified by
hagen-Riska, in a recent review, suggested that overall prophylactic venography [22]. Routine use of prophylac-
patient survival was approximately 83% at 10 years com- tic anticoagulation has not been the norm in most centers
pared with 88% for an age- and sex-matched Finnish [23, 24]. However, an article by Sarasin and Schifferli
control population [13]. Other studies have reported sim- suggested, using a decision model, that the benefits of
ilar long-term survival. For patients with NS, Honkanen prophylactic anticoagulation outweighed the risks and
et al reported a 10-year survival of 70%, irrespective of that it should be routine for all patients with NS second-
the treatment given [13]. ary to idiopathic membranous nephropathy [25]. Prophy-
Schieppati et al reported on the course in 100 patients lactic anticoagulation should certainly be considered in
who received no therapy other than supportive treat- patients felt to be at high risk for venous thrombosis,
ment [6]. The incidence of remission of proteinuria in-
that is, those with severe or prolonged nephrotic rangecreased over time such that at five years, 65% were in
proteinuria. This has not yet been subjected to a random-complete or partial remission, whereas only 16% pro-
ized controlled trial. A firm recommendation thus cannotgressed to end-stage renal disease (ESRD). The benign
be made.course of these patients may, in part, be explained by
Over the past 30 years, many different treatment regi-the modest degree of proteinuria. Fully 37% had nonne-
mens have been recommended for the treatment of idio-phrotic-range proteinuria (that is, less than 3.5 g/day),
pathic membranous nephropathy. The heterogeneity ofwhereas 56% had less than 5 g/day.
study designs, treatment regimens, enrollment criteria,In contrast, the prognosis of membranous nephropa-
outcomes, and follow-up data has lead to considerablethy seems to be much more benign in women, children,
difficulty in interpreting the results of these many studies.younger adults, and those with secondary (drug-induced)
There are a number of prospective, randomized trialsdisease [8, 16–18]. Patients in whom proteinuria is less
addressing a variety of treatment regimens, but with verythan 3.5 g/day or who maintain normal renal function
variable results. The lack of consistent results favoringfor the first three years also have a good prognosis [4].
one treatment over another is what lies behind the cur-
rent debate on the optimal treatment of idiopathic mem-
METHODS
branous nephropathy.
This article focuses on a critical review of the extensive
published literature in the area, with an emphasis on the Recommendations
levels of evidence for the validity of the studies cited, Recommendation 1. There is no benefit of either a
using the guidelines developed by Carruthers et al for short or prolonged course of oral, alternate-day steroids
studies of treatment [19]. A total of more than 200 arti- for either inducing remission of NS or preserving renal
cles was identified from a MEDLINE search covering function in patients with membranous nephropathy. Corti-
the period from 1970 to 1997, using the key words mem- costeroids should not be used as sole therapy (grade A).
branous nephropathy and therapy. Abstracts were re- Evidence. There have been three large, prospective,
viewed and articles selected for in-depth review using randomized, placebo-controlled clinical trials (RCTs) of
the criteria proposed by Carruthers et al [19].
corticosteroid therapy for membranous nephropathy (Ta-
ble 1) published between 1979 and 1990 [26–28]. These
MANAGEMENT OF IDIOPATHIC studies are comparable in terms of the clinical and demo-
MEMBRANOUS NEPHROPATHY graphic characteristics of the patients. End points were
similar, although there were differences in the definitionsEvaluation of the effectiveness of treatment strategies
for idiopathic membranous nephropathy is substantially of partial and complete remissions of the NS.
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Table 1. Corticosteroid treatment in idiopathic membranous nephropathy
Author Level of
[reference] evidence N Treatment regimen Results/comments
CSAINS [26] 1 72 Prednisone 100–150 mg p.o. on Rapid decline in renal function in controls. Prednisone
alternate days 3 8–12 weeks associated with more complete or partial remissions
vs. placebo of NS.
Cameron [27] 1 107 Prednisone 125–150 mg p.o. on No difference in renal function or proteinuria at 36
alternate days 3 8 weeks months. Modest early (3 and 6 month) benefit on uri-
vs. placebo nary protein excretion.
Cattran [28] 1 158 Prednisone 45 mg/m2 on No difference in remission rates for NS in either short
alternate days 3 6 months (6 and 12 month) or long (48 month) term. No differ-
vs. placebo ences in rates of progression of renal insufficiency.
Abbreviations are: p.o., oral; NS, nephrotic syndrome.
The U.S. Collaborative Study of Adult Idiopathic Ne- nisone could reverse or stabilize progressive renal failure
in patients with advanced idiopathic membranous ne-phrotic Syndrome [26], the smallest of the three RCTs,
reported that a minimum of eight weeks of high-dose (100 phropathy [31]. This observation is, as yet, unconfirmed.
Recommendation 3. Treatment with alkylating agentsto 150 mg, depending on body weight), alternate-day pred-
nisone resulted in a significant reduction in the rate of induces prolonged remission of membranous nephropa-
thy. Because most controlled trials have used corticoste-progression to renal failure. The short follow-up period
and poorer than expected outcome in the placebo group roids in combination with alkylating agents, it is recom-
mended that both be used. Specific recommendations[4, 5] have led to criticism of the results of this study.
However, some authors continue to recommend this re- regarding timing, dose, and duration of therapy are pro-
vided in Table 2 and Figure 1. Given the potential toxicitygime for patients with early histological disease and per-
sistent NS, despite the lack of any evidence for benefit, of these therapies, they should be reserved for patients
at high risk of progression to renal failure (grade A).citing the relative safety of therapy as justification [7].
The British Medical Research Trial [27] duplicated Evidence. Despite the widespread use of cyclophos-
phamide and chlorambucil in patients with idiopathicthe effort of the U.S. study but with a larger patient
population and a longer duration of follow-up (minimum membranous nephropathy, the clinical trial evidence on
which these treatments are based consists of a numberof 3 years). This study was unable to demonstrate any
significant effect of a short course of corticosteroids on of small uncontrolled studies [32–36] and just six pro-
spective RCTs [37–42], which vary in study design, entryrenal function or urinary protein excretion at three years,
although there was a modest early beneficial effect on criteria, and outcomes evaluated (Table 2).
Many of the smaller trials suffer from significant meth-urinary protein excretion and serum albumin noted at
three to six months. odological flaws, in that they are either retrospective or
lack the statistical power, because of sample size consid-The study of the Toronto Glomerulonephritis Study
Group evaluated a much longer (six months) course of erations, to allow firm conclusions to be drawn. As such,
the data presented in these studies must be interpretedoral, alternate-day prednisone in a lower dose (45 mg/m2)
than the earlier studies on the outcome of idiopathic with caution. However, Lagrue et al, in a retrospective
study, noted complete or partial remission of proteinuriamembranous nephropathy [28]. After a median follow-
up period of 48 months, there was no difference in the in 13 out of 16 patients with membranous nephropathy
who were treated with chlorambucil compared with justrates of decline in creatinine clearance or in the propor-
tions of patients in either partial or complete remission. 3 out of 14 on placebo and 1 out of 11 on azathioprine
[32]. In contrast, neither Shearman et al nor AlexopoulosNo early benefits were noted.
Recommendation 2. Azathioprine should not be used et al found any benefits from oral cyclophosphamide
compared with either corticosteroids or symptomaticas part of routine care for this condition (grade C).
Evidence. Few studies have addressed the effects of therapy in their retrospective studies [35, 36].
Donadio et al conducted a study of 22 patients ran-azathioprine either alone or in combination with steroids
in membranous nephropathy. Those that have addressed domized to either oral cyclophosphamide of 1.5 to 2.5
mg/kg daily or no specific therapy for a period of 12these effects suggest that it is largely ineffective in either
inducing remission of NS or preventing renal insuffi- months [37]. There was no effect of cyclophosphamide
on renal function, proteinuria, or histological stage ofciency [29, 30]. A recent uncontrolled study did, however,
suggest that the addition of oral azathioprine to a regime disease. Falk et al conducted a randomized controlled
trial of intravenous and oral corticosteroids plus intrave-of intravenous pulse methylprednisolone and oral pred-
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Table 2. Cytotoxic treatment in idiopathic membranous nephropathy
Author Level of
[reference] evidence N Treatment regimen Results/comments
Ponticelli [39] 1 67 MP 1 g i.v. 3 3 days; 0.4 mg/kg p.o. 3 27 days, Well-conducted study. All patients had NS, but patients
then chlorambucil 0.2 mg/kg p.o. 3 28 days 3 with renal insufficiency excluded. Increased rate of par-
3 cycles vs. symptomatic therapy tial/complete remission in treatment group vs. declining
in controls.
Ponticelli [42] 1 92 MP 1 g i.v. 3 3 days; 0.4 mg/kg p.o. 3 27 days, Chlorambucil associated with earlier remission of NS.
then chlorambucil 0.2 mg/kg/day 3 28 days for
3 cycles vs. MP alone. On alternate months 3
6 months
Donadio [37] 2 22 Cyclophosphamide 1.5 to 2.5 mg/kg Small study. No favorable impact of cyclophosphamide
p.o. 3 1 year vs. symptomatic therapy on proteinuria, renal function or histology.
Ponticelli [43] 1 67 MP 1 g i.v. 3 3 days; 0.4 mg/kg p.o. 3 27 days, 10 year follow-up data from above study. Significant im-
then chlorambucil 0.2 mg/kg p.o. 3 28 days 3 provement in renal survival for chlorambucil vs. symp-
3 cycles vs. symptomatic therapy tomatic therapy.
Murphy [41] 2 40 Cyclophosphamide 1.5 mg/kg 3 6 months 1 di- No differences in renal function at 2 years. Treatment
pyridamole/warfarin 3 2 years vs. symptom- group had significantly less proteinuria and higher serum
atic therapy albumin through follow-up.
Falk [38] 2 26 Prednisone 2 mg/kg vs. cyclophosphamide 0.5 No impact of cyclophosphamide on renal function, pro-
g/m2 1 i.v. pulse and oral steroids (7 mg/kg gression to ESRD or level of proteinuria.
methylprednisone, then prednisone 2 mg/kg)
for 6 months
West [40] 3 26 Cyclophosphamide 2 mg/kg 3 20 6 4 months 6 High-risk patients with significant renal failure and/or pro-
prednisone vs. prednisone or symptomatic longed NS. Cyclophosphamide associated with an in-
therapy creased rate of remission of NS and better preservation
of renal function.
Abbreviations are: MP, methylprednisolone; NS, nephrotic syndrome; other abbreviations are in Table 1.
nous cyclophosphamide compared with oral corticoste- rate studies of chlorambucil in the treatment of idio-
pathic membranous nephropathy. The first of these, pub-roids alone in 26 patients with idiopathic membranous
nephropathy and clinical and laboratory evidence of de- lished in 1984, was a RCT of six months treatment with
chlorambucil plus corticosteroids in monthly cycles ver-terioration [38]. Over a mean follow-up period of 29.2 6
17.1 months, there were no differences between the rate sus symptomatic therapy, in patients with nephrotic
range proteinuria related to idiopathic membranous ne-of progression to ESRD (4 out of 13 in each group)
nor in the severity of renal failure or urinary protein phropathy [39]. Impressive results favoring the treatment
group were reported, with 23 out of 32 chlorambucilexcretion. West et al conducted a case-control study of
oral cyclophosphamide versus oral corticosteroids (in 15 patients experiencing a complete or partial remission
compared with just 9 out of 30 control patients. Theout of 17 control subjects) in idiopathic membranous
nephropathy [40]. They were able to conclude that ther- second study, published in 1992, compared the chloram-
bucil/steroid regimen with steroids alone in 92 nephroticapy with cyclophosphamide was associated with improve-
ment in both serum albumin and 24-hour proteinuria, patients with idiopathic membranous nephropathy [42].
None of the patients had participated in the earlier study.while preserving renal function and delaying progression
to ESRD. This study is remarkable for its selection of a Again, a net benefit favoring the chlorambucil-treated
patients was apparent, both for remission of NS (66%group of patients at high risk for progression, that is,
persistent proteinuria of more than 3.5 g/day and serum free of NS at three years vs. 40% in control) and preser-
vation of renal function. This study suggested that treat-creatinine of more than 135 mmol/liter.
Murphy et al studied 40 patients randomized to either ment with chlorambucil/methylprednisone was less likely
to induce a remission in the presence of renal insuffi-no specific therapy or a treatment regimen consisting of
oral cyclophosphamide for six months and oral warfarin ciency or mesangial sclerosis.
Ponticelli et al have recently published data concern-and dipyridamole for two years [41]. Renal function was
unchanged during two years of follow-up in both groups, ing 10-year outcomes in their original cohort of 81 pa-
tients prospectively randomized to symptomatic therapybut reduced proteinuria and improved serum albumin
were found in the cyclophosphamide-treated patients. compared with cyclic treatment with intravenous methyl-
prednisolone, oral prednisone, and oral chlorambucilWhen only those patients with the NS are considered,
a significantly higher proportion of patients in the treat- [43]. All of these patients had NS at the time of initial
treatment assignment, in contrast to other prospectivement group achieved a complete remission compared with
control patients (9 out of 13 vs. 4 out of 13, P 5 0.05). studies and to studies of untreated patients, in which a
variable percentage of patients had non-nephrotic pro-Ponticelli et al have published the results of two sepa-
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Fig. 1. Treatment algorithm for idiopathic membranous nephropathy. *Chlorambucil may be preferable to cyclophosphamide with respect to
toxicity.
teinuria. Ten-year follow-up revealed that the probabil- with renal insufficiency were not excluded [28]. The 10-
year renal survival of 72% reported by Schieppati inity of renal survival was 0.92 (95% CI, 0.83 to 1.00) for
treated patients compared with 0.60 (95% CI, 0.42 to untreated patients from the same region of Italy as Ponti-
celli’s patients must be interpreted with caution, as 37%0.78) for controls. This raises the question of whether
Ponticelli’s control patients may have experienced an of their patients had nonnephrotic range proteinuria and
56% had less than 5 g/day of proteinuria [6]. Massiveunduly rapid progression of renal failure. In contrast,
Cattran et al reported an actuarial survival, using a creati- proteinuria has been identified in a number of studies
as an important risk factor for progression [4, 8], al-nine clearance of 0.16 ml/seconds as the end point, of 91
versus 90% at eight years for control versus prednisone- though the recent meta-analyses have failed to demon-
strate this as an independent risk factor, perhaps becausetreated patients [28]. Cattran et al’s patients were very
similar to Ponticelli’s in all respects except that patients of methodological limitations. The relative rarity of mas-
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Table 3. Cyclosporine treatment in idiopathic membranous nephropathy
Author Level of
[reference] evidence N Treatment regimen Results/comments
Cattran [49] 2 17 CsA 3.5 mg/kg/day 3 12 months CsA associated with slower rate of decline in renal func-
vs. placebo tion. Sustained remission of proteinuria in 6/8 CsA
patients.
Rostoker [47] 5 15 CsA 4–5 mg/kg 3 12–30 months 11/15 had complete or partial remission of NS. Relapse
Prednisone 1–2 mg/kg/day 3 2 seen in 3/9 on CsA withdrawal. No CsA nephrotox-
months icity.
DeSanto [46] 6 5 CsA 7 mg/kg 3 6 months 1 MP All had failed prior to chlorambucil/MP therapy. 4/5
1–3 mg/kg/day, decreasing to had prompt remission of proteinuria. No renal failure.
0.15 mg/kg/day Follow-up brief.
Radhakrishnan [48] 6 10 CsA 4–6 mg/kg 3 6–43 months 6 SLE-associated membranous nephropathy 6/10 had re-
prednisone mission of proteinuria. No worsening of renal failure.
Abbreviations are: MP, methylprednisolone; NS, nephrotic syndrome; CsA, cyclosporine.
sive proteinuria (only 10% of patients had proteinuria progression [49]. Of 64 patients followed initially on a
low-protein diet, 17 had persistent nephrotic range pro-in excess of 10 g/day) may further explain the relatively
benign course undergone by the patients described by teinuria and a rate of decline in creatinine clearance in
excess of 8 ml/min/year, and were randomized to cyclo-Schieppati et al [6].
Several small studies have examined the effects of sporine or placebo. After 12 months of drug therapy,
patients on cyclosporine had a significantly slower ratechlorambucil or cyclophosphamide on the outcome of
membranous nephropathy in patients with more advanced of decline in renal function and less proteinuria than
placebo-treated patients. These benefits persisted for updisease [44, 45]. In both of these studies, patients had
severe and/or persistent NS (24-hr protein of more than to two years after the withdrawal of cyclosporine. These
results are certainly encouraging, but will need to be3.5 g for more than six months) and renal insufficiency
(serum creatinine of more than 159 mmol/liter) prior to confirmed by a larger trial with a more prolonged follow-
up period, given the natural history of the disease.cytotoxic therapy. Both treatments have been associated
with an improvement in both the degree of proteinuria
Meta-analyses of studies in idiopathicand rate of decline in renal function despite the presence
membranous nephropathyof advanced histological disease, severe proteinuria, and
renal failure. This observation is important, as most of Two meta-analyses of clinical trials in idiopathic mem-
branous nephropathy have recently been published [50,the patients in the RCTs of both chlorambucil and cyclo-
phosphamide had normal renal function prior to treat- 51]. Imperiale, Goldfarb, and Berns conducted a detailed
examination of the five randomized prospective clinicalment. It may be that patients selected on the basis of a
higher risk of progression will be more likely to benefit trials of cyclophosphamide and/or chlorambucil in this
disease [50]. In contrast to the often very large numbersfrom alkylating agents. However, this remains to be stud-
ied in a clinical trial of adequate size and duration. of patients reported in retrospective studies focused ei-
ther on therapy or natural history, these five studiesRecommendation 4. Cyclosporine therapy shows prom-
ise as an effective therapy for patients with membranous collectively involve just 228 patients. Even in this small
group of studies, there is still considerable heterogeneitynephropathy who are at high risk for progressive renal
failure (grade B). Cyclosporine of 4 to 6 mg/kg daily for in the doses and duration of drug therapy, mean duration
of follow-up, definitions of complete and partial re-12 months is the preferred regimen.
Evidence. A number of trials have addressed the use sponses to treatment and comparison therapies used.
However, despite these shortcomings, this meta-analysisof cyclosporine, usually in conjunction with steroids, for
the treatment of idiopathic membranous nephropathy provides evidence suggesting that, for some patients at
least, there are benefits to the use of alkylating agents.(Table 3), as well as membranous lupus nephritis [46–49].
The usual dose of cyclosporine used in these studies has For all of the trials, the relative risk (RR) of achieving
a complete remission in the treatment group (urine pro-been 4 to 6 mg/kg. The majority of studies have been
uncontrolled yet have shown promising results with re- tein of less than 0.2 to 0.5 g/day) was 4.6 (95% CI, 3.2
to 8.4). When just the RCTs were included in the meta-spect to both remission of NS and preservation of renal
function, together with freedom from serious cyclosporine analysis, the RR was 3.4 (95% CI, 1.6 to 7.1). There
were no qualitative or quantitative differences noted innephrotoxicity.
Cattran et al recently reported the results of a random- complete remission rates for cyclophosphamide com-
pared with chlorambucil treatment. Calculation of theized trial of cyclosporine in patients with idiopathic mem-
branous nephropathy who were felt to be at high risk of number needed to treat (NNT) to produce one complete
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Table 4. Recommendations regarding drug therapy in idiopathicremission (calculated as the reciprocal of the absolute
membranous nephropathy
difference in event rate between treatment and control
1. Cyclophosphamidegroups) yielded a value of 4.7 both for all trials and for
• 1.5 to 2.5 mg/kg/day orally for six to twelve months with 1 to 2
trials comparing cytotoxic therapy with symptomatic treat- mg/kg/day alternate day prednisone for the first two months [40,
41]. Prednisone should be tapered as soon as a response is evident.ment only. This study did not address the issue of long-
• The dose of cyclophosphamide should be adjusted to maintainterm effects of therapy on renal function, owing to the
total WBC . 4.5 3 109/liter.
lack of clear renal outcome data in the source material. • Intravenous pulse cyclosphosphamide should not be used [54].
2. ChlorambucilHogan et al conducted a less rigorous yet more exten-
• Pulse methylprednisolone 1 g i.v. 3 three days followed by 0.4sive examination of 32 studies published between 1968 mg/kd/day orally for 27 days. Chlorambucil 0.2 mg/kg/day for 28
and 1993 [51]. This analysis comprised a second meta- days.
• Cycle repeated 3 three for a total duration of six months [39,analysis of the prospective trials noted earlier here, as
42].
well as pooled analyses, including many retrospective • Chlorambucil dose should be adjusted to maintain total WBC .
4.5 3 109/liter.studies and case series for which relevant outcome data
The dose of both cyclophosphamide and chlorambucil shouldcould be gleaned from the published articles. In this way,
be based on an estimate of ‘dry’ or pre-nephrotic weight to
the analysis was able to include data on close to 2000 avoid marrow toxicity.
3. Cyclosporinepatients followed, in most cases, for more than two years.
• 4 to 6 mg/kg/day in two divided doses for six to twelve monthsThe meta-analysis again found that the RR for complete [46–49]. Dose should be adjusted to maintain monoclonal whole
remission in patients treated with alkylating agents was blood trough level of 120 to 200 ng/ml.
• Prednisone 1 to 2 mg/kg on alternate days may be added [46–48]4.8 (95% CI, 1.44 to 15.96). The results of the pooled
as above, but should be tapered as soon as a response is evident.
analysis revealed that renal survival, however, was no
Abbreviations are: WBC, white blood cells; i.v., intravenous.
different at two years between alkylating therapy and
either the symptomatic therapy or steroid groups. At
five years, there was a lower probability of renal survival
CONCLUSIONSin the steroid/no-therapy group (0.80) than in patients
receiving alkylating agents (0.99). Despite the large number of clinical studies with vari-
able outcome measures and treatment regimes, it is pos-
Toxicity of cytotoxic therapy sible to draw some reasonably firm conclusions (Table
The conclusions that can be drawn from studies of 4 and Fig. 1). First, data from the three randomized
controlled trials suggest that, on balance, there is nocytotoxic therapy for membranous nephropathy are nec-
justification for the continued use of corticosteroidsessarily tempered by concern regarding the potential
alone as primary therapy for patients with NS caused bytoxicities of both chlorambucil and cyclophosphamide,
idiopathic membranous nephropathy. There is even lessas well as continued anxiety concerning the long-term
justification to use corticosteroids in patients without NS.outcome of therapy. Although Ponticelli et al’s most
Second, the spontaneous favorable outcome in manyrecent follow-up study may allay the latter fear [43, 52],
patients with idiopathic membranous nephropathy andmany physicians remain reluctant to commit their pa-
NS, with up to 40% of patients entering complete remis-tients to cytotoxic therapy, preferring to use corticoste-
sion, often delayed, does not justify the routine use ofroids despite clear evidence that they are ineffectual.
cytotoxic therapy for all patients even with NS. However,A recent article highlighted the potential long-term
a meta-analysis of the RCTs of cytotoxic therapy forconsequences of cyclophosphamide therapy. Talar-Wil-
membranous nephropathy indicates that there are long-liams et al evaluated the occurrence of bladder cancer
term benefits on both the remission of NS and the rate
in patients who had received cyclophosphamide as ther-
of progression of renal failure. Cytotoxic therapy should
apy for Wegener’s granulomatosis at the National Insti- therefore be offered to all patients who are felt to be at
tutes of Health between 1967 and 1993 [53]. They found high risk of progression based on clinical factors such as
that prolonged cyclophosphamide therapy, particularly age, male gender, renal function, blood pressure, severity
at cumulative doses in excess of 100 g, was associated and persistence of NS, or histological presence of severe
with an increased rate of development of bladder cancer. tubulointerstitial disease. Meta-analysis of RCTs does
The bladder cancer risk was estimated to be 5% at 10 not indicate a preference for chlorambucil over cyclo-
years and 16% at 16 years after first exposure to cyclo- phosphamide. The recent publication by Ponticelli et al
phosphamide. A cumulative dose of 100 g requires some of a randomized comparison of cyclophosphamide versus
19 months of therapy for a 70 g patient on 2.5 mg/kg chlorambucil suggests that the therapies should be con-
daily. It remains to be seen what effect, if any, this finding sidered equivalent in terms of efficacy [52]. Both drugs
will have on the use of cyclophosphamide for glomerular are associated with significant short- and long-term toxic-
ity. The recent report of a significant increase in the riskdiseases of all kinds.
Muirhead: Membranous nephropathyS-54
8. Wehrmann M, Bohle A, Bogenschutz O, Eisele R,of bladder cancer many years after initiation of treatment
Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner
with cyclophosphamide [53] suggests that chlorambucil H-V: Long-term prognosis of chronic idiopathic membranous glo-
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